RS67746B1 - Farmaceutski prihvatljiva so atrasentana za upotrebu u metodi lečenja iga nefropatije - Google Patents
Farmaceutski prihvatljiva so atrasentana za upotrebu u metodi lečenja iga nefropatijeInfo
- Publication number
- RS67746B1 RS67746B1 RS20260142A RSP20260142A RS67746B1 RS 67746 B1 RS67746 B1 RS 67746B1 RS 20260142 A RS20260142 A RS 20260142A RS P20260142 A RSP20260142 A RS P20260142A RS 67746 B1 RS67746 B1 RS 67746B1
- Authority
- RS
- Serbia
- Prior art keywords
- atrasentan
- weeks
- pharmaceutically acceptable
- subject
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| EP20903533.6A EP4076652B1 (en) | 2019-12-17 | 2020-12-16 | A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy |
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS67746B1 true RS67746B1 (sr) | 2026-03-31 |
Family
ID=76478538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260142A RS67746B1 (sr) | 2019-12-17 | 2020-12-16 | Farmaceutski prihvatljiva so atrasentana za upotrebu u metodi lečenja iga nefropatije |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20260121T1 (hr) | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| JP2025517355A (ja) * | 2022-05-19 | 2025-06-05 | チヌーク セラピューティクス,インコーポレイテッド | アトラセンタンを用いた巣状分節性糸球体硬化症の治療方法 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| US20260130933A1 (en) * | 2022-10-05 | 2026-05-14 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for prevention or treatment of nephropathy and/or diabetes mellitus, comprising enavogliflozin |
| AU2023366516A1 (en) * | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| WO2024099272A1 (zh) * | 2022-11-07 | 2024-05-16 | 信瑞诺医药(上海)有限公司 | 用于治疗IgA肾病的内皮素受体拮抗剂和糖皮质激素的组合 |
| TW202604476A (zh) * | 2024-06-21 | 2026-02-01 | 大陸商深圳信立泰藥業股份有限公司 | 內皮素a(eta)受體拮抗劑聯用sglt-2抑制劑的醫藥用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| AU2003221042A1 (en) | 2002-03-22 | 2003-10-08 | Kissei Pharmaceutical Co., Ltd. | Preventive or therapeutic agent for kidney disease |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
| WO2006034234A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 3 of atrasentan hydrochloride |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034085A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form of atrasentan hydrochloride |
| US20060189675A1 (en) | 2004-09-17 | 2006-08-24 | Steve King | Crystalline form of a drug |
| WO2007109244A2 (en) | 2006-03-21 | 2007-09-27 | Morehouse School Of Medicine | Novel nanoparticles for delivery of active agents |
| KR20080108570A (ko) * | 2006-03-27 | 2008-12-15 | 제넨테크, 인크. | 신장 질환을 치료하는 방법 |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| ZA200902814B (en) | 2007-01-16 | 2010-08-25 | Musc Found For Res Dev | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| CN101801936B (zh) | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2011070049A1 (en) | 2009-12-09 | 2011-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| CN103025670B (zh) | 2010-07-28 | 2016-08-10 | 日本电气硝子株式会社 | 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法 |
| JP2016512201A (ja) * | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
| US9855245B2 (en) | 2013-04-30 | 2018-01-02 | Abbvie Inc. | Methods for improving lipid profiles using atrasentan |
| PE20160221A1 (es) | 2013-07-08 | 2016-05-22 | Abbvie Inc | Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| WO2016073846A1 (en) * | 2014-11-07 | 2016-05-12 | Abbvie Inc. | Methods of treating ckd using predictors of fluid retention |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| IL300122A (en) * | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| CA3010593C (en) | 2016-01-05 | 2024-02-13 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| JP2019530713A (ja) * | 2016-10-13 | 2019-10-24 | レトロフィン, インコーポレイテッド | 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 |
| IL294410B2 (en) | 2016-11-23 | 2024-02-01 | Chemocentryx Inc | A method for the treatment of focal segmental tuberous sclerosis |
| MX386699B (es) | 2017-10-11 | 2025-03-19 | Chemocentryx Inc | Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2 |
| LT3716979T (lt) | 2017-11-30 | 2025-07-10 | Idorsia Pharmaceuticals Ltd | 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| HRP20260121T1 (hr) | 2019-12-17 | 2026-03-13 | Chinook Therapeutics, Inc. | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije |
| US20230270718A1 (en) | 2020-04-10 | 2023-08-31 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 HR HRP20260121TT patent/HRP20260121T1/hr unknown
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 SI SI202030727T patent/SI4076652T1/sl unknown
- 2020-12-16 FI FIEP20903533.6T patent/FI4076652T3/fi active
- 2020-12-16 DK DK20903533.6T patent/DK4076652T3/da active
- 2020-12-16 RS RS20260142A patent/RS67746B1/sr unknown
- 2020-12-16 PL PL20903533.6T patent/PL4076652T3/pl unknown
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 EP EP25219043.4A patent/EP4710928A3/en active Pending
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 TW TW114152252A patent/TW202615002A/zh unknown
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 PT PT209035336T patent/PT4076652T/pt unknown
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 TW TW114114616A patent/TWI914232B/zh active
- 2020-12-16 LT LTEPPCT/US2020/065311T patent/LT4076652T/lt unknown
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-08-16 US US17/888,766 patent/US12582631B2/en active Active
-
2023
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-11-29 US US18/523,609 patent/US12521369B2/en active Active
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP7821870B2/ja active Active
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
-
2026
- 2026-01-26 JP JP2026010769A patent/JP2026090302A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20260121T1 (hr) | Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije | |
| ES3065958T3 (en) | Extended release dosage forms for tyk2 inhibitors | |
| IL254768A0 (en) | Method and device for treating vascular disease | |
| IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
| HK1245078A1 (zh) | 治疗神经退行性疾病的方法 | |
| IL287470A (en) | Compounds containing n-methyl-2-pyridone and pharmaceutically acceptable salts | |
| GB2573257B (en) | Method and machine for producing titanium cobbles | |
| DE112020004223A5 (de) | Schrägwalzaggregat sowie Verfahren zum Anstellen des Walzkalibers eines Schrägwalzaggregats | |
| SI3377041T1 (sl) | Postopek delitve in/ali targetiranja farmacevtsko aktivnih učinkovin sinovialnemu tkivu | |
| IL286949A (en) | Mesitantan for use in the treatment of portopulmonary hypertension | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| HUE067967T2 (hu) | Szarakatinib idiopátiás tüdõfibrózis kezelésében történõ alkalmazásra | |
| GB2586489B (en) | Method and structures for coil adjustment | |
| SG11201705635XA (en) | Method for configuring a ballast water treatment system and related system | |
| IL286818B2 (en) | Mirikizumab for use in the treatment of Crohn's disease | |
| CA195802S (en) | Roller head for skin treatment apparatus | |
| GB2598483B (en) | Apparatus for facilitating pivotal movement of implements in machines | |
| SI4072532T1 (sl) | Dozirna oblika za uporabo v zdravljenju ali preprečevanju bolezni | |
| IL279511A (en) | PRC2 subunit inhibitors for use in the treatment of ocular disorders | |
| PL3533518T3 (pl) | Autoklaw oraz sposób usuwania soli z autoklawu | |
| ZA201701772B (en) | Pharmaceutical formulation for reducing bladder spasms and method of use thereof | |
| ES3066019T3 (en) | Btk inhibitor for use in the treatment of iga nephropathy or purpura nephritis | |
| EP3579886A4 (en) | METHOD OF USE FOR THERAPEUTIC BONE ASSOCIATION | |
| HK40060614A (en) | Mirikizumab for use in a method of treating crohn's disease | |
| GB202020445D0 (en) | Method and apparatus for storing energy |